New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 31, 2013
09:06 EDTAGN, MAPPAllergan commences tender offer for MAP Pharmaceuticals
Allergan (AGN)'s wholly-owned subsidiary, Groundhog Acquisition, has commenced a tender offer to purchase all outstanding shares of common stock of MAP Pharmaceuticals (MAPP) for $25.00 per share, net to the seller in cash, without interest and less any applicable withholding taxes. The board of directors of MAP has unanimously agreed to recommend that MAPís stockholders accept the tender offer and tender their shares to Purchaser. The tender offer and withdrawal rights are scheduled to expire at 12:00 midnight, NYC time, on the night of February 28, unless extended.
News For AGN;MAPP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
September 24, 2014
09:11 EDTAGNValeant sends letter to Allergan CEO and lead independent director
Subscribe for More Information
09:04 EDTAGNValeant CEO sent letter to Allergan to extend 'olive branch,' CNBC reports
Subscribe for More Information
09:02 EDTAGNAllergan pursuit of Salix continues to be slowed, CNBC's Faber says
Subscribe for More Information
09:02 EDTAGNActavis, Salix in early merger talks, CNBC's Faber reports
Subscribe for More Information
06:23 EDTAGNExperts see new tax rules not halting inversions, WSJ reports
Subscribe for More Information
September 23, 2014
16:13 EDTAGNPershing's Ackman sends letter to Allergan, threatens suit
Subscribe for More Information
12:28 EDTAGNSalix climbs after reports say Allergan discussing takeover
Subscribe for More Information
12:11 EDTAGNOn The Fly: Midday Wrap
Stocks on Wall Street were mixed and little changed at midday, amid new rules from the Obama administration on tax inversions and manufacturing data from around the globe. ECONOMIC EVENTS: In the U.S., the FHFA's home price index rose 0.1% in July to 212.7, missing expectations for a rise of 0.5%. Markit's preliminary manufacturing Purchasing Managers' Index for September came in at 57.9, slightly below the consensus forecast for a 58.0 reading. The Richmond Fed manufacturing index for September rose to 14, beating expectations for it to have dropped two points to 10. In China, HSBC's flash manufacturing Purchasing Managers' Index rose to 50.5 from a final reading of 50.2 in August, better than expectations. In Europe, Markit's composite flash PMI for the eurozone dipped to a nine-month low of 52.3, missing expectations for it to hold steady at the 52.5 seen in August. COMPANY NEWS: Shares of several companies, including a number in the pharmaceutical industry, are lower in early trading after the Treasury Department announced new regulations yesterday night that aim to make it tougher for U.S. companies to lower their tax burdens via mergers with foreign companies, otherwise known as "inversions." Among the stocks that moved lower after the new rules were announced was Astrazeneca (AZN), which had previously been a target of Pfizer (PFE) and fell about 4% near midday. Also lower were shares of both Shire (SHPG), which fell 2%, and Abbvie (ABBV), which dropped 1.6%, as the two have previously agreed to merge in a tax inversion deal. Medtronic (MDT) and Covidien (COV), which similarly agreed to an inversion merger, were down 3.3% and 2.7%, respectively. MAJOR MOVERS: Among the notable gainers was Salix Pharmaceuticals (SLXP), which rose more than 5% after The Wall Street Journal reported that Allergan (AGN) is in advanced talks on a deal to buy the company. Shares of Allergan were also up nearly 3% near midday, as the Journal also reported that Allergan rejected a recent buyout offer from Actavis (ACT). Among the noteworthy losers was Ascena Retail (ASNA), which dropped 16% after the apparel retailer's fourth quarter results and fiscal 2015 profit outlook trailed analysts' consensus estimates. Also lower following its own earnings report was auto retailer CarMax (KMX), which fell over 9%. INDEXES: Near midday, the Dow was down 32.91, or 0.19%, to 17,139.77, the Nasdaq was up 2.90, or 0.06%, to 4,530.59, and the S&P 500 was down 2.29, or 0.11%, to 1,992.00.
10:54 EDTAGNStocks, analysts react to Treasury inversion crackdown
Subscribe for More Information
09:17 EDTAGNSalix, Allergan just started talks over price, CNBC reports
Subscribe for More Information
09:13 EDTAGNOn The Fly: Pre-market Movers
Subscribe for More Information
08:53 EDTAGNInversion regulations look more onerous than expected, says FBR Capital
FBR Capital says the new regulations announced last night by the Treasury and IRS contain appear more onerous than expected. FBR points out the proposed changes remove the ability of inverting companies to make "hopscotch loans" between the foreign and domestic subsidiaries. The firm believes the regulations will not end the practice of inversions, and it still expects completion of already announced deals.
08:38 EDTAGNPershing threatens suit against Allergan if no vote held on Salix deal, WSJ says
Subscribe for More Information
08:31 EDTAGNSalix takeout price could be $200 per share, says Leerink
Leerink estimates a takeout valuation for Salix (SLXP) of $200 per share, but says it would start recommending investors take profits above $185. The firm believes a potential deal with Allergan (AGN) would likely include an above-average break-up fee. Leerink thinks a competitive bid could surface, and points out Actavis (ACT) has more overlapping cost structure with Salix than Allergan. Shares of Salix are up 9% to $173.48 in pre-market trading after Wall Street Journal reported the company is in merger talks with Allergan.
06:28 EDTAGNTreasury rules may put Mylan deal at risk, says BMO Capital
BMO Capital believes Treasury's new inversion rules may put the tax benefits of Mylan's (MYL) planned acquisition of Abbott's (ABT) established products business at risk. BMO also thinks the rules impact Salix's (SLXP) pending deal for Cosmo Pharmaceuticals, which it feels may help make a deal with Allergan (AGN) more likely.
05:56 EDTAGNTreasury, IRS announce plans to reduce inversion tax benefits
Subscribe for More Information
September 22, 2014
19:03 EDTAGNAllergan rejected buyout bid from Actavis, in advanced talks for Salix, WSJ says
Subscribe for More Information
September 19, 2014
11:25 EDTAGNSenators bring bill requiring companies to settle before inverting
U.S. Senators Sherrod Brown and Dick Durbin announced new legislation requiring corporations to "Pay What You Owe Before You Go" Ė settling their U.S. tax bill before relocating to a foreign country. "Everyone knows that before you leave a restaurant you have to settle your tab," Brown said. "Corporations shouldnít get to play by different rules. While it is critical that we reach a long-term solution that reforms our international corporate tax code by implementing a global minimum tax and reducing the statutory tax rate, this bill is an immediate, commonsense measure to ensure businesses settle up before leaving the U.S." Among the deals or possible transactions that involve inversion are Mylan's (MYL) acquisition of Abbott (ABT), Medtronic's (MDT) acquisition of Covidien (COV) and Valeant's (VRX) proposed takeover of Allergan (AGN).
September 16, 2014
11:51 EDTAGNOECD looks to close tax loopholes with new proposals
Subscribe for More Information
05:37 EDTAGNValeant, Pershing Square, Allergan settle pending litigation before DE Court
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use